Promoting HPV Vaccination Among Young Adults in Texas

Last updated: January 20, 2026
Sponsor: M.D. Anderson Cancer Center
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Gynecological Infections

Human Papilloma Virus (Hpv)

Neoplasms

Treatment

Experimental arm 2

Informational Intervention

Questionnaire Administration

Clinical Study ID

NCT05057312
2020-1142
NCI-2021-09416
P30CA016672
R01CA248216
2020-1142
5R01CA248216-02
  • Ages 18-26
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

This clinical trial studies how to improve the human papillomavirus (HPV) vaccination rate in young adults in Texas. This trial aims to learn more about how researchers and health care providers can increase HPV vaccination among college students.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age 18-26 years. This criterion is based on the CDC recommendation of vaccination upto 26 years of age and the fact that individuals 18 years and older can consent bythemselves for on-site vaccination

  • Ability to read and understand English

  • Self-identification as not yet having received any HPV vaccine injections.Self-identification is justified because it is safe to be vaccinated again, whichcould happen if a previously vaccinated person forgets their vaccination.Furthermore, in a person previously vaccinated with an older version of the vaccine,which targeted fewer HPV types, receiving the newer version would be advantageousand not cause any harm. Alternatives to self-identification, such as obtainingmedical records from doctors' offices, would be very challenging for young adults,especially for those who do not remember when and where they might have receivedvaccination

  • Access to a smart phone, tablet or computer that is connected to the internet

  • Current enrollment in one of the participating schools with an anticipatedcontinuous enrollment of at least 9 months

Exclusion

Exclusion Criteria:

  • Being pregnant

  • Having a life-threatening allergy to any component of the HPV vaccine

Study Design

Total Participants: 1200
Treatment Group(s): 9
Primary Treatment: Experimental arm 2
Phase:
Study Start date:
July 26, 2021
Estimated Completion Date:
July 31, 2026

Study Description

PRIMARY OBJECTIVES:

I. To determine the impact of addressing individual and system levels of influence on HPV vaccination initiation and completion rates.

II. To gain insight into mechanisms of the intervention's efficacy, individual differences, and implementation of the intervention using mixed methods.

OUTLINE: Participants are randomized to 1 of 6 groups.

GROUP I: Participants receive standard Centers for Disease Control and Prevention (CDC) information about HPV vaccination.

GROUP II: Participants receive video narratives about HPV vaccination.

GROUP III: Participants receive written narratives about HPV vaccination.

GROUP IV: Participants receive enhanced access to vaccination and standard CDC information about HPV vaccination.

GROUP V: Participants receive enhanced access to vaccination and video narratives about HPV vaccination.

GROUP VI: Participants receive enhanced access to vaccination and written narratives about HPV vaccination.

After completion of study, participants are followed up at 3 and 9 months.

Connect with a study center

  • M D Anderson Cancer Center

    Houston, Texas 77030
    United States

    Site Not Available

  • M D Anderson Cancer Center

    Houston 4699066, Texas 4736286 77030
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.